{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T09:01:18Z","timestamp":1773910878064,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["ZCLQN25H0304"],"award-info":[{"award-number":["ZCLQN25H0304"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s10067-025-07571-0","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T23:07:59Z","timestamp":1753139279000},"page":"3539-3547","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Discontinuation of belimumab in systemic lupus erythematosus patients who achieved disease stability: a retrospective cohort study"],"prefix":"10.1007","volume":"44","author":[{"given":"Yanxia","family":"Ren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5196-9426","authenticated-orcid":false,"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"issue":"9","key":"7571_CR1","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41584-021-00668-1","volume":"17","author":"MRW Barber","year":"2021","unstructured":"Barber MRW, Drenkard C, Falasinnu T et al (2021) Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol 17(9):515\u2013532. https:\/\/doi.org\/10.1038\/s41584-021-00668-1","journal-title":"Nat Rev Rheumatol"},{"key":"7571_CR2","doi-asserted-by":"publisher","unstructured":"Chinese Rheumatology Association, National Clinical Research Center for Dermatologic and Immunologic Diseases, Chinese Systemic Lupus Erythematosus Treatment and Research Group (2020) 2020 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus. Zhonghua nei ke za zhi 59(3):172-185. https:\/\/doi.org\/10.2478\/rir-2020-0009","DOI":"10.2478\/rir-2020-0009"},{"key":"7571_CR3","doi-asserted-by":"publisher","unstructured":"D\u00f6rner T, Kinnman N, Tak PP (2010) Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol Ther 1125(3):464\u2013475.\u00a0https:\/\/doi.org\/10.1016\/j.pharmthera.2010.01.001","DOI":"10.1016\/j.pharmthera.2010.01.001"},{"key":"7571_CR4","doi-asserted-by":"publisher","unstructured":"Zhang J, Roschke V, Baker KP et al (2001) Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 166(1):6\u201310.\u00a0https:\/\/doi.org\/10.4049\/jimmunol.166.1.6","DOI":"10.4049\/jimmunol.166.1.6"},{"key":"7571_CR5","doi-asserted-by":"publisher","unstructured":"Petri M, Stohl W, Chatham W et\u00a0al (2008) Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 58(8):2453\u20132459.\u00a0https:\/\/doi.org\/10.1002\/art.23678","DOI":"10.1002\/art.23678"},{"key":"7571_CR6","doi-asserted-by":"publisher","unstructured":"Roth DA, Thompson A, Tang Y et al (2016) Elevated blys levels in patients with systemic lupus erythematosus: associated factors and responses to belimumab. Lupus 25(4):346\u2013354. https:\/\/doi.org\/10.1177\/0961203315604909","DOI":"10.1177\/0961203315604909"},{"key":"7571_CR7","doi-asserted-by":"publisher","unstructured":"Zhao X, Zhang J, Liang Y et al (2021) Advances in drug therapy for systemic lupus erythematosus. CURR MED CHEM 28(6):1251-1268.\u00a0https:\/\/doi.org\/10.1186\/1741-7015-8-77","DOI":"10.1186\/1741-7015-8-77"},{"key":"7571_CR8","doi-asserted-by":"publisher","unstructured":"Stohl W, Hiepe F, Latinis KM et al (2012) Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 64(7):2328-2337.\u00a0https:\/\/doi.org\/10.1002\/art.34400","DOI":"10.1002\/art.34400"},{"key":"7571_CR9","doi-asserted-by":"publisher","unstructured":"Chiang HY, Guo ZA, Wu TW et al (2022) Efficacy and safety of belimumab therapy in systemic lupus erythematosus: a systematic review and meta-analysis. LUPUS 31(6):666-673. https:\/\/doi.org\/10.1177\/09612033221090888","DOI":"10.1177\/09612033221090888"},{"key":"7571_CR10","doi-asserted-by":"publisher","unstructured":"Anjo C, Mascar\u00f3 JM, Espinosa G et al (2019) Effectiveness and safety of belimumab in patients with systemic lupus erythematosus in a real-world setting. Scand J Rheumatol 48(6):469-473.\u00a0https:\/\/doi.org\/10.1080\/03009742.2019.1603324","DOI":"10.1080\/03009742.2019.1603324"},{"key":"7571_CR11","doi-asserted-by":"publisher","unstructured":"Zhang F,\u00a0Bae SC,\u00a0Bass D et al (2018) A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis 77(3):355-363.\u00a0https:\/\/doi.org\/10.1136\/annrheumdis-2017-211631","DOI":"10.1136\/annrheumdis-2017-211631"},{"key":"7571_CR12","unstructured":"GSK. Belimumab prescribing information (2023) Available: https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Benlysta\/pdf\/BENLYSTA-PI-MGIFU.PDF. Accessed\u00a019 Jul 2025"},{"key":"7571_CR13","doi-asserted-by":"publisher","unstructured":"Cho J,\u00a0Lahiri M,\u00a0Teoh LK et al (2019) Predicting flares in patients with stable systemic lupus erythematosus. Semin Arthritis Rheu 49(1):91-97.\u00a0https:\/\/doi.org\/10.1016\/j.semarthrit.2019.01.001","DOI":"10.1016\/j.semarthrit.2019.01.001"},{"key":"7571_CR14","doi-asserted-by":"publisher","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A et al (2019) 2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78(6):736-745. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215089","DOI":"10.1136\/annrheumdis-2019-215089"},{"key":"7571_CR15","doi-asserted-by":"publisher","unstructured":"Franklyn K, Lau CS, Navarra SV et al (2016) Definition and initial validation of a lupus low disease activity state (LLDAS). Ann Rheum Dis 75(9):1615\u20131621. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207726","DOI":"10.1136\/annrheumdis-2015-207726"},{"key":"7571_CR16","doi-asserted-by":"publisher","unstructured":"Sarnes E, Crofford L, Watson M et al (2011) Incidence and US costs of corticosteroid\u2010associated adverse events: a systematic literature review. Clin Ther 33(10):1413\u20101432. https:\/\/doi.org\/10.1016\/j.clinthera.2011.09.009","DOI":"10.1016\/j.clinthera.2011.09.009"},{"key":"7571_CR17","doi-asserted-by":"publisher","unstructured":"Murphy G, Isenberg DA (2019) New therapies for systemic lupus erythematosus-past imperfect, future tense. Nat Rev Rheumatol 15(7):403-412. https:\/\/doi.org\/10.1038\/s41584-019-0235-5","DOI":"10.1038\/s41584-019-0235-5"},{"key":"7571_CR18","doi-asserted-by":"publisher","unstructured":"Ruiz-Arruza I,\u00a0Ugarte A,\u00a0Cabezas-Rodriguez I et al (2014) Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatology 53(8):1470-1476.\u00a0https:\/\/doi.org\/10.1093\/rheumatology\/keu148","DOI":"10.1093\/rheumatology\/keu148"},{"key":"7571_CR19","doi-asserted-by":"publisher","unstructured":"Lu C, He N, Dou L et al (2024) Belimumab in early systemic lupus erythematosus: a propensity score matching analysis. Immun Inflamm Dis 12(8):e1362.\u00a0https:\/\/doi.org\/10.1002\/iid3.1362","DOI":"10.1002\/iid3.1362"},{"key":"7571_CR20","doi-asserted-by":"publisher","unstructured":"Wallace DJ, Ginzler EM, Merrill JT et al (2014) Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol 41(2):300-309.\u00a0https:\/\/doi.org\/10.3899\/jrheum.121368","DOI":"10.3899\/jrheum.121368"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07571-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07571-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07571-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T07:50:17Z","timestamp":1756453817000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07571-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["7571"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07571-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"assertion":[{"value":"8 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was approved by the Medical Ethics Committee of the Second Affiliated Hospital of Jiaxing University (ethics approval number: 2023-ZFYJ-005-01) and was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Patient and\/or the public were not involved in the design, conduct, reporting, or dissemination plans of this research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient and public involvement"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"The authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}